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This study examined the effects of an oral nutritional supplement fortified with two different doses of
beta-alanine on body composition, muscle function and physical capacity in older adults. Using a double-
blind placebo controlled design, 60 men and women (age ± SD = 70.7 ± 6.2 yrs) were randomly assigned
to one of three treatment groups: 1) oral nutritional supplement (ONS; n = 20) (8 oz; 230 kcal; 12 g PRO;
31 g CHO; 6 g FAT), 2) ONS plus 800 mg beta-alanine (ONS800; n = 19), and 3) ONS plus 1200 mg
beta-alanine (ONS1200; n = 21). Treatments were consumed twice per day for 12 weeks. At pre- and
post-supplementation period, participants performed a discontinuous, submaximal cycle ergometry test to
determine physical working capacity at fatigue threshold (PWCFT). Fat mass, total body and arm lean soft tis-
sue mass (ALSTM) were measured with DEXA while muscle strength was assessed with handgrip dynamom-
etry (GRIP) and 30-s sit-to-stand (STS) was used to measure lower body functionality. Muscle quality (MQ)
was calculated with GRIPmax and DEXA derived ALSTM [GRIP (kg)·ALSTM (kg)− 1]. Two-way analysis of
variance was used to compare pre- to post-supplementation measures and group differences. There were
16 dropouts over the duration of the study. Final group sizes were ONS = 16 (m = 11, w = 5),
ONS800 = 15 (m = 5, w = 10), and ONS1200 = 13 (m = 6, w = 7). No significant changes were ob-
served for body composition or GRIP values pre to post. Significant increases in PWCFT were seen in
ONS1200 (13.6%) and ONS800 (17.8%) pre- to post-supplementation (p b 0.05). These changes were sig-
nificantly greater (p b 0.05) than the changes in ONS (−6.3%). ONS1200 and ONS had significant in-
creases in STS (22.2 and 10.7%, respectively). While ONS significantly increased in STS, no differences
(p N 0.05) in change scores were found between ONS and ONS800. ONS fortified with beta-alanine may
improve physical working capacity, muscle quality and function in older men and women. These findings
could have importance in the perception of frailty, and the maintenance of health and independent living
in older adults.
1. Introduction
Sarcopenia is an age-related condition characterized by a loss of
skeletal muscle mass, with accompanying loss of strength, power, and
the ability to resist fatigue (Brooks and Faulkner, 1994; Chandler and
Hadley, 1996). These modifications may be the result of changing skel-
etal muscle morphology, including both a decrease in size and loss of
type I and II muscle fibers (Doherty, 2003) and an increase in fat and
connective tissue infiltration,whichhas been shown to decreasemuscle
quality (MQ) (Cadore et al., 2012; del Favero et al., 2012). Muscle qual-
ity has been shown to be associatedwith strength, power and anaerobic
threshold in an older population (Cadore et al., 2012; Fukumoto et al.,
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2012). Cadore et al. (2012) recently suggested that the age related de-
crease in MQ, due to the increase in intramuscular fat and connective
tissue, may be associated with a decrease in the number of capillaries.
This change in capillary density may disrupt the blood supply to adja-
cent muscle fibers and impair cardiorespiratory capacity resulting in
the inability to resist fatigue at relatively low workloads due to anaero-
bic acidosis.
In addition to a decrease in MQ, several studies have shown a de-
crease in muscle carnosine levels in older adults (Baguet et al., 2012;
Everaert et al., 2011; Stuerenburg and Kunze, 1999; Tallon et al.,
2007). Carnosine is a dipeptide that works as an intramuscular hydro-
gen ion (H+) buffer (Harris et al., 1990, 2006). The decrease in muscle
carnosine levels may lead to a decrease in buffering capacity of the
muscle, diminishing the ability to withstand the build-up of H+ during
anaerobic activities (Stout et al., 2008). With a decrease in MQ and
carnosine content, daily activities like walking up stairs may result in
muscle acidosis and lead to an inability to continue due to fatigue. The
ability to resist fatigue may be important due to its potential relation-
ship with balance, gait speed, and increased risk of falls, which has
been related to an increased risk of injury and death (Alexander et al.,
1997; Chandler and Hadley, 1996; del Favero et al., 2012; Kannus et
al., 2005; Madureira et al., 2010; Stout et al., 2008).
There are a couple of factors that may cause this decrease in
carnosine concentration with age. β-Alanine is the rate limiting amino
acid for muscle carnosine synthesis which occurs naturally in the diet
(e.g., chicken and fish) (Harris et al., 2006). The first possible cause for
the decrease inmuscle carnosine, therefore, may be due to amovement
towards amore vegetarian diet, or a dietwith a smaller amount of fresh
meat as opposed to processedmeat (Everaert et al., 2011; Kim, 2009). In
support, one study of the elderlywhere itwas known that subjectswere
continuing to eat a high meat (mainly chicken and fish) diet, muscle
carnosine levels were unchanged when compared with a young popu-
lation from the same country (Kim, 2009). The second cause of a de-
crease in muscle carnosine with aging is an atrophy of type II muscle
fibers with area occupied decreasing (Tallon et al., 2007). Thus in a
given volume or weight of muscle there will be less type II muscle
even if the percentage of fibers has not changed, i.e. they just got thin-
ner. Thus even if the carnosine content per kg ofmuscle does not change
in either type I and IImuscle fibers therewill appear to be a reduction in
the content of carnosine at the whole muscle level (Tallon et al., 2007).
Several studies have shown thatmuscle carnosine content increases
significantly following β-alanine supplementation (Baguet et al., 2010;
del Favero et al., 2012; Harris et al., 2006; Hill et al., 2007) and is directly
related to an increase in exercise capacity. Two studies (del Favero et al.,
2012; Stout et al., 2008) have shown a significant increase in exercise
capacity in older adult populations following β-alanine supplemen-
tation. Recently, del Favero et al. (2012) demonstrated a significant
increase (+85.4%) in muscle carnosine levels in an older adult popula-
tion (65 ± 4 yrs) following 3.2 g·day−1 of β-alanine supplementation
over an 84 day period. Following the supplementation period there
were significant increases in time to exhaustion at a constant workload
on a treadmill (36.5%) and in time to exhaustion during an incremental
treadmill test (12.2%). In support, Stout et al. (2008) observed a 28.6%
increase in physical working capacity at fatigue threshold (PWCFT)
following 12-weeks of β-alanine supplementation (2.4 g·day−1) in
older (72.8 ± 11.1 years) men and women. Therefore, data showing
β-alanine supplementationmay improve PWCmay have significant im-
plications for the aging population.
The improvements in exercise capacity seen in older adults with
β-alanine supplementation appear to be effective at moderate
(3.2 g·day−1) and low (2.4 g·day−1) doses for more than 84 days,
however, no study to our knowledge has investigated whether a very
low dose (1.6 g·day−1) has similar efficacy in this population. The pri-
mary purpose of this study was to determine the effect of 12-weeks of
β-alanine added to a commercially available oral nutrition supplement
(ONS) on PWCFT, MQ, muscle strength, and muscle function in an older
adult population. This study was a preliminary examination testing the
safety and efficacy of adding β-alanine to a commercially available
product that people over the age of 60 commonly consume. We know
of no studies to date that have examined the effects of β-alanine
added to an ONS. A secondary purpose was to examine the efficacy
of two lower dose levels (2.4 g·day−1 and 1.6 g·day−1) of β-alanine
added to the ONS on the performance measures. Previous studies (Del
Favero et al., 2012; Stout et al., 2008) have provided evidence that
higher doses of β-alanine improved endurance capacity in a similar
cohort of men and women; however, the higher dosing may produce
paresthesia in some people. Therefore it is important to determine if a




Sixty oldermen (n = 27) andwomen (n = 33) fromCentral Florida
volunteered to participate in this double-blind, placebo-controlled
study. A medical history questionnaire and interviews with participants
prior to the testing revealed no one was supplementing with beta-
alanine prior to the study period. No participants had major surgery
within the previous 6 months, or a history of asthma, uncontrolled
heart or pulmonary disease, uncontrolled hypertension, or were taking
any medications that would interfere with exercise. All procedures
were approved by the University Institutional Review Board. Following
an explanation of all related risks and benefits associated with the ex-
perimental protocol, each participant gave his or her written informed
consent to participate in the study.
2.2. Experimental design
Immediately following baseline testing, participantswere random-
ly assigned to one of three treatment conditions. Each group supple-
mented with 8 liquid ounces (227 g) of a commercially available
oral ONS containing 230 kcal, 12 g of protein, 31 g of carbohydrate,
and 6 g of fat (Ensure High Protein, Abbott Nutrition). Group 1
ingested ONS only (n = 20); group 2 ingested ONS plus 800 mg
β-alanine (ONS800; n = 19); and group 3 ingested ONS plus 1200 mg
β-alanine (ONS1200; n = 21). Supplements were consumed twice
per day for 12-weeks. The ONS was fortified with Carnosyn™, non-
sustained release powder, β-alanine. The two dose levels of β-alanine
used to fortify the ONSwere examined to determine if they produce sig-
nificant exercise improvements while attenuating the potential pares-
thesia observed in previous studies. The ONS was produced from the
same batch and therefore the ingredient make-up was identical, with
the exception of the addition of the β-alanine. At the outset of the
study, participants were briefed on the number of calories in the
ONS and dietary strategies to maintain an isocaloric diet in order
to maintain weight throughout the study. Additionally, participants
were asked to continue their normal daily exercise routine if they
were exercising. Participants were asked to refrain from vigorous
physical activity the day before testing. During each visit, partici-
pants were questioned to confirm compliance with the study proto-
col as directed. To measure compliance, participants returned
empty bottles or bottle caps. Compliance for each group during
the 12 week supplementation was: ONS =95%, ONS800 = 93%,
and ONS1200 = 90%.
Participants were instructed to complete a three-day dietary recall
at pre- and post-testing. Participants were instructed to write down
everything consumed during two weekdays and one weekend day.
These data were entered into a software program (Food Works 13,
The Nutrition Company, Long Valley, NJ) which provided calculations
for daily protein intake (g) and total calories (kcal).
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Of the 60 participants that enrolled in the study, 44 completed
follow-up testing. One participant was excluded for initiation of oral
creatine supplementation following baseline testing, another for a sick-
ness contracted late in the study, and the rest were voluntary dropouts
due to personal reasons. Two of the dropouts from the ONS1200 group
cited paresthesia as the reason for dropping out. Four other participants
in the ONS1200 group noted paresthesia, but were willing to continue
with the study. No dropouts from the ONS800 group noted paresthesia
as the reason for leaving the study. One person from the ONS800 group
did experience paresthesia, but was willing to continue with the study.
Final group sizes were ONS = 16 (m = 11, w = 5), ONS800 = 15
(m = 5, w = 10), and ONS1200 = 13 (m = 6, w = 7). Characteris-
tics of those participants who completed the study are presented in
Table 1. In addition, Table 2 presents information detailing the medi-
cines, supplements, and physical activity of those participants complet-
ing the study. Using the procedures described by Gravettier and
Wallnau (1996) for estimating sample sizes for repeated measures de-
signs, a minimum sample size of n = 12 was required for each group
to reach a statistical power (1 − β) of 0.80 based on the findings of
Stout et al. (2008).
2.3. Measures
Dual-energy X-ray absorptiometry (DEXA) (GE Lunar Prodigy,
Madison, WI) was performed to estimate fat mass, total body lean soft
tissue mass (TLSTM) and arm lean soft tissue mass (ALSTM) pre and
post supplement period. During both visits, participants performed a
discontinuous, cycle ergometry test on an electronically-braked cycle
ergometer to determine the physical working capacity at fatigue
threshold (PWCFT), a handgrip dynamometry test (GRIP) to assessmus-
cle strength, and a 30-s sit-to-stand test (STS) to measure lower body
functionality. To ensure safety from a hematological standpoint, a fasted
blood draw was performed at the university health center at pre and
post supplementation. Samples were analyzed at a commercial labora-
tory for complete blood counts and general blood chemistry.
2.4. Electromyography (EMG) measurements
Abipolar (4.6 cmcenter-to-center) surface electrode (QuintonQuick-
Prep silver-silver chloride) arrangement was placed over the right vastus
lateralis muscle, at approximately 60% of the distance from the lateral
portion of the patella on a line with the greater trochanter. The reference
electrode was placed over the lateral epicondyle of the distal femur.
Inter-electrode impedance was kept below 5000 Ω with abrasion of the
skin beneath the electrodes. The raw EMG signals were pre-amplified
using adifferential amplifier (MP150BIOPACSystems, Inc., Santa Barbara,
CA), sampled at 1000 Hz, and stored on a personal computer (Dell
Latitude E6530, Dell Inc., Round Rock, TX) for off-line analysis. The EMG
signals were expressed as root mean square (rms) amplitude values
(μV rms) by software (AcqKnowledge v4.2, BIOPAC Systems, Inc., Santa
Barbara, CA).
2.5. Determination of PWCFT
Determination of PWCFT values was previously described by de
Vries et al. (1987) for the vastus lateralis. The initial work rate was
set at 30 W for each test. The participants pedaled at 50 revolutions
per minute (rpm) for two-minute stages on an electronically-braked
cycle ergometer (Lode, Excalibur Sport, Groningen, Netherlands).
Toe clips were utilized for each participant. Following each stage of
exercise, the EMG-rms amplitude valueswere saved on a personal com-
puter and further analyzed with custom-written software (LabView,
National Instruments Corporation, Austin, TX). If the exercise stage
did not produce a statistically significant (p b 0.05), positive slope of
the amplitudes (rms) across the two-minute work bout, the resistance
was increased 10–20 W until a significant, positive amplitude (rms)
slope was achieved or the participant reached 75% of their age-
predicted maximal heart rate, or surpassed a rating of perceived exer-
tion (RPE) of 13 (“Somewhat Hard”) on the Borg scale. If a significant,
positive amplitude (rms) slope was reached, one final stage was
performed at 5–10 W less than the resistance of the stage that produced
the significant, positive slope. The PWCFT was estimated to be themean
resistance of the highest non-statistically significant positive slope and
the lowest statistically significant positive slope. In the event the par-
ticipant did not have a statistically significant, positive amplitude
(rms) slope during any stage of their PWCFT, a regression analysis was
performed utilizing the amplitude (rms) slope for each two-minute
stage against each corresponding workload (watts). The y-intercept
(watts) produced in this analysis was then used as the PWCFT (de
Vries et al., 1982).
Test–retest reliability for the PWCFT test was determined from 10
participants who were randomly selected from the ONS (control)
group that were measured 40 days apart. The intraclass correlation
coefficient (ICC) was 0.95 (SEM = 13.7 W). No significant difference
Table 1
Baseline participant characteristics of those completing study.
Treatment group Age (yrs) Height (cm) Weight (kg) BMI
ONS (n = 16, m = 11/w = 5) 70.6 ± 6.8 165.3 ± 16.3 77.8 ± 17.3 29.9 ± 7.2
ONS800 (n = 15, m = 5/w = 10) 70.8 ± 6.1 164.8 ± 10.2 73.7 ± 11.5 28.7 ± 6.0
ONS1200 (n = 13, m = 6/w = 7) 72.4 ± 6.4 169.9 ± 11.3 87.4 ± 25.8 27.1 ± 3.2
Values reported as mean ± standard deviation (SD).
Table 2






















Taking no supplements 10/23%
Physical activity
Structured physical activityb 30/68%
Physically activec 5/11%
Sedentary 9/21%
a Participants = only those completing the study (n = 44).
b At least twice·week−1.
c Activities included gardening, housework, etc.
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(p N 0.05) was noted between the mean PWCFT values from trial 1
(69.5 ± 44.1 W) to trial 2 (68.5 ± 43.3 W). In addition, the ICC
(0.95) and SEM (12.3 W) for estimating PWCFT from plotting the
slopes of EMG-rms versus time against each workload revealed no
significant differences between the estimated mean PWCFT values
from trial 1 (46.7 ± 12.3W) to trial 2 (51.1 ± 11.1W). These ICC re-
sults were similar to de Vries et al. (1989) and Stout et al. (2008)
who reported ICC values of 0.97 and 0.83, respectively in older adults.
2.6. Determination of strength measures
During the GRIP, participants were standing with the hand grip
dynamometer (JAMAR, Sammons Preston Rolyan, Bolingbrook, IL) in
their dominant hand. The dynamometer handle was adjusted so
that the middle phalange of the third digit was comfortably perpen-
dicular to the long axis of the handle. The arms were adducted with
the dynamometer held at a 90° angle to their body. Participants
were instructed to squeeze the handle as hard as they could for
three to five seconds. Verbal encouragement was provided to illicit
maximum effort. The participants performed three trials. GRIP values
were recorded to the nearest whole number (kg). Average (GRIPAVG)
for the three trials and maximum (GRIPMAX) values were recorded.
Test–retest reliability for the GRIP test was determined using 16 par-
ticipants from the control group measured 40 days apart. The ICC was
0.94 (SEM = 4.5 kg). There was no significant difference (p N 0.05)
between the mean GRIP values from trial 1 (35.7 ± 3.1 kg) to trial
2 (34.9 ± 3.1 kg).
Muscle quality (MQ) was calculated as relative strength with
GRIPMAX and DEXA derived ALSTM [GRIP (kg)·ALSTM (kg)−1]. Test–
retest reliability for the MQ was determined by using 16 participants
from the control group measured 40 days apart. The ICC was 0.68
(SEM = 1.58 kg·kg−1). There was no significant difference (p N 0.05)
between the mean MQ values from trial 1 (12.32 ± 2.06 kg·kg−1) to
trial 2 (12.18 ± 1.87 kg·kg−1).
During the STS, participants sat in an armless chair with their arms
crossed over their chest and upon first movement the timer started
the stopwatch. Participants stood to a vertical position then sat down
on the chair, repeating this process for 30 s. STS values were recorded
to the nearest whole number, for those repetitions that the participant
made it to a complete standing position. Test–retest reliability for the
STS test was determined by using 16 participants from the control
group measured 40 days apart. The ICC was 0.96 (SEM = 1.8). There
was a significant difference (p = 0.026) between the mean STS values
from trial 1 (17.5 ± 5.76) to trial 2 (18.6 ± 6.42).
2.7. Statistical analysis
A two-way [treatment (ONS vs. ONS800 vs. ONS1200) × time (pre
vs. post)] Analysis of Variance (ANOVA) was used to analyze the data.
If baseline values were different between the groups or as a follow-up
to significant interaction, then an Analysis of Covariance (ANCOVA)
was utilized to analyze differences between groups. If significant in-
teractions were observed, then Tukey post hoc pair-wise comparisons
were used to examine group differences. In addition, follow-up to a
significant main effect included paired sample t-tests for each group
over time. For effect size, the partial eta squared statistic was calcu-
lated and a value of 0.01, 0.06, and 0.14 were used to represent
small, medium, and large effect sizes, respectively. An alpha level of
p b 0.05 was used to determine statistical significance. Data were
analyzed using SPSS v20 software (SPSS Inc., Chicago, IL).
3. Results
3.1. Body mass and dietary analysis
There were no significant changes in body weight, lean soft tissue,
or fat mass across the time period for any group. There were no signif-
icant differences (p N 0.05) from pre- to post-supplement for protein
intake or total calories consumed (Table 3). With no difference in pro-
tein intake it is believed that there were no changes in carnosine in-
take with the exception of those participants consuming ONS800
and ONS1200.
3.2. Blood analysis
The results of the pre- to post-supplementation blood analysis are
presented in Table 4. Results revealed that 2 measures (glucose and
mean corpuscular hemoglobin concentration) were outside the nor-
mal range at the beginning of the period for all three groups. Glucose
stayed outside the normal range at post-supplement testing for all
groups. With no measures moving outside the normal range, it ap-
pears β-alanine supplementation is safe from a hematological stand-
point in older adults.
3.3. PWCFT
There was a significant interaction (p = 0.005; η2 = 0.23) for
group × time for pre- to post-supplement. Groups ONS1200 and
ONS800 exhibited significant (p b 0.05) improvements in their PWCFT,
while group ONS did not show an improvement in PWCFT. Table 5 pre-
sents the mean and standard deviation values for the PWCFT for each
group aswell as the percent change values frompre- to post supplemen-
tation testing. Of note, when the statistics are recomputed excluding
those participantswho experienced paresthesia, the statistical difference
remained the same. Groups ONS800 and ONS12000 experienced signif-
icant increases in PWCFT, and these two groups were not significantly
different.
3.4. Strength measures
There were no significant differences in GRIPMAX or GRIPAVG for
group × time for pre- to post-supplement. There was a significant
group x time interaction (p = 0.024; η2 = 0.167) for STS from pre- to
post-supplement. Each group showed improvement with group ONS
and ONS1200 showing significant improvement over time (Table 5).
When post-supplement values were adjusted for the initial differences
Table 3
Dietary protein and caloric intake differences pre to post supplementation.
Treatment Dietary protein content (g) Total caloric intake (kcal)
Mean (g) Mean (kcal)
Pre Post pa Pre Post pa
ONS1200 78.72 ± 32.59 95.69 ± 22.31 0.171 1767.11 ± 730.31 2165.22 ± 436.71 0.777
ONS800 84.77 ± 25.87 87.39 ± 18.59 0.772 2103.4 ± 552.09 1974.6 ± 497.67 0.361
ONS 84.77 ± 25.87 79.36 ± 19.05 0.129 2204.08 ± 774.35 1983.34 ± 630.31 0.354
Values reported as mean ± standard deviation (SD).
a p value represents pre to post difference.
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in pre-supplement values, the increase in STS value was significant-
ly greater for ONS1200 versus ONS800 (p = 0.021). There was no dif-
ference between groups ONS and ONS800. There was a significant
difference in group x time interaction (p = 0.039; η2 = 0.146) for
MQHANDGRIP from pre- to post-supplement. Groups ONS and ONS800
did not show any improvement, but groupONS1200 showed a trend to-
wards improvement (p = 0.06) of 7.4%.When post-supplement values
are adjusted for initial differences, group ONS1200 showed a signifi-
cantly greater increase than ONS800 and ONS (Fig. 1).
4. Discussion
The main findings in this study suggest that 12-weeks of a very
low (800 mg twice daily) and low (1200 mg twice daily) amount of
β-alanine added to anONSmay increase PWCFT, aswell asmuscle func-
tion and quality measures in older adults. These results add support to
previous research showing that regardless of age or gender, β-alanine
supplementation, even at relatively low doses, may improve perfor-
mance across a variety of physical tasks, including functionality and en-
hancing muscular endurance. Exercise capacity in the present study
was measured using PWCFT, which has been shown to be a valid
measure of fitness in older adults (de Vries et al., 1989). The ONS800
group showed a significant improvement in performance of 17.8%,
while the ONS1200 group showed a significant increase of 13.6%
(Table 5) following supplementation, however, therewas no significant
difference between these two groups (p = 0.547). The effect size ob-
served in this study for exercise capacity (η2 = 0.23) is comparable to
effect sizes (0.12–1.129) reported for several studies using similar
total β-alanine dosing (109 to 189 g) (Hobson et al., 2012). Post hoc
analysis of changes relative to body weight suggests little difference
between groups ONS800 and ONS1200. This may be the reason why
there was no significant difference between these two groups. Future
studies should try and control for dose level and body weight when
selecting dose levels. However, our results are about 10% lower than
Table 4
Pre to post supplementation hematological results.
Variable ONS1200 (n = 13) ONS (n = 16) ONS800 (n = 15)
Pre Post Pre Post Pre Post
Sodium (mmol/L) 140.00 ± 3.74 140.00 ± 2.35 142.19 ± 3.15 140.88 ± 2.25 142.20 ± 2.78 141.87 ± 1.85
Potassium (mmol/L) 5.09 ± 0.46 4.99 ± 0.46 4.78 ± 0.37 5.13 ± 0.54a 5.05 ± 0.56 4.92 ± 0.36
Chloride (mmol/L) 104.77 ± 3.54 104.15 ± 2.97 104.94 ± 2.77 105.88 ± 1.71 104.93 ± 2.66 104.87 ± 2.29
Total CO2 (mmol/L) 28.00 ± 1.83 25.54 ± 4.01a 28.19 ± 2.14 27.39 ± 1.93 27.33 ± 3.02 26.93 ± 2.58
Anion gap (mmol/L) 7.00 ± 2.49 9.45 ± 3.67 8.69 ± 2.24 7.63 ± 2.63 9.93 ± 3.31 9.93 ± 2.20
Glucose (mg/dL) 113.92 ± 32.00a 114.08 ± 31.23b 101.31 ± 11.91c 100.56 ± 10.97b 102.33 ± 10.17c 100.60 ± 14.94b
Urea nitrogen (mg/dL) 21.58 ± 8.04 22.69 ± 7.32 21.69 ± 5.44 22.75 ± 10.04 21.00 ± 5.36 22.20 ± 4.66
Creatinine (mg/dL) 1.04 ± 0.30 1.05 ± 0.22 1.14 ± 0.27 1.18 ± 0.33 0.88 ± 0.18 0.93 ± 0.16
BUN/creatinine ratio 20.92 ± 4.60 21.38 ± 3.86 19.38 ± 3.52 18.94 ± 3.80 24.53 ± 6.65 24.40 ± 5.05
Calcium (mg/dL) 9.54 ± 0.35 9.54 ± 0.44 9.40 ± 0.31 9.55 ± 0.26a 9.63 ± 0.38 9.71 ± 0.25
Total protein (g/dL) 7.05 ± 0.34 6.99 ± 0.37 6.84 ± 0.28 6.88 ± 0.27 7.17 ± 0.43 7.10 ± 0.32
Albumin (g/dL) 4.42 ± 0.24 4.08 ± 0.93 4.28 ± 0.18 4.26 ± 0.20 4.37 ± 0.24 4.34 ± 0.15
Globulin (g/dL) 2.63 ± 0.29 2.66 ± 0.25 2.57 ± 0.24 2.63 ± 0.27 2.80 ± 0.42 2.76 ± 0.33
A/G ratio 1.70 ± 0.22 1.65 ± 0.16 1.69 ± 0.19 1.64 ± 0.21 1.59 ± 0.25 1.59 ± 0.21
Total bilirubin (mg/dL) 0.58 ± 0.17 0.58 ± 0.26 0.58 ± 0.19 0.64 ± 0.23a 0.53 ± 0.16 0.68 ± 0.25a
Alkaline phosphatase (U/L) 57.31 ± 14.65 59.80 ± 13.18 64.44 ± 12.58 67.50 ± 16.30 64.40 ± 14.78 65.00 ± 13.79
AST (U/L) 22.92 ± 10.48 20.77 ± 4.44 22.06 ± 6.72 24.75 ± 14.32 25.33 ± 12.80 27.00 ± 21.60
ALT (U/L) 19.15 ± 9.48 17.69 ± 4.37 18.69 ± 7.84 19.69 ± 8.10 24.13 ± 23.48 26.93 ± 34.82
Cholesterol (mg/dL) 168.69 ± 27.70 167.62 ± 24.95 177.13 ± 40.65 168.19 ± 32.15 180.80 ± 19.89 174.27 ± 14.26
Triglycerides (mg/dL) 142.00 ± 48.70 140.85 ± 63.43 98.63 ± 45.21 101.00 ± 38.63 111.33 ± 31.46 123.20 ± 53.72
HDL cholesterol (mg/dL) 51.92 ± 14.91 53.46 ± 19.80 54.94 ± 14.50 54.00 ± 16.17 58.73 ± 10.62 55.20 ± 10.95
LDL cholesterol (mg/dl) 88.38 ± 31.67 85.77 ± 24.64 102.44 ± 35.59 9 3.94 ± 24.37 99.80 ± 19.38 94.53 ± 13.21
VLDL cholesterol (mg/dL) 28.08 ± 10.21 28.39 ± 12.81 19.75 ± 9.09 20.25 ± 7.68 22.27 ± 6.34 24.53 ± 10.83
Risk ratio (CHOL/HDL) 3.45 ± 0.97 3.23 ± 0.78 3.36 ± 0.93 3.28 ± 0.82 3.14 ± 0.52 3.26 ± 0.54
WBC (×10b/μL) 6.09 ± 1.23 6.57 ± 2.66 5.79 ± 1.58 6.05 ± 1.87 5.91 ± 1.88 5.84 ± 1.80
RBC (M/μL) 4.40 ± 0.51 4.36 ± 0.53 4.75 ± 0.43 4.71 ± 0.49 4.67 ± 0.32 4.67 ± 0.36
Hemoglobin (g/dL) 13.53 ± 1.45 13.47 ± 1.02 14.41 ± 1.02 1 4.15 ± 1.12 14.31 ± 0.92 14.16 ± 1.10
Hematocrit (%) 42.36 ± 4.50 41.21 ± 4.39a 45.55 ± 2.93 44.06 ± 3.48a 45.75 ± 2.93 43.97 ± 3.11a
MCV (fL) 96.49 ± 4.30 94.82 ± 4.03a 96.23 ± 4.95 93.89 ± 3.80a 97.97 ± 3.35 94.35 ± 2.70a
MCH (pg) 30.82 ± 1.16 30.93 ± 1.42 30.45 ± 1.63 30.19 ± 1.66 30.65 ± 1.18 30.37 ± 1.06a
MCHC (g/dL) 31.97 ± 0.87c 32.65 ± 1.14a 31.64 ± 0.56c 32.13 ± 0.81a 31.27 ± 0.65c 32.21 ± 0.70a
Platelets (×10b/μL) 251.31 ± 83.96 240.31 ± 60.67 245.06 ± 50.80 235.69 ± 57.22 247.47 ± 71.58 244.20 ± 80.33
RDW 13.48 ± 0.84 13.46 ± 1.14 13.29 ± 0.62 13.29 ± 0.70 13.31 ± 0.96 13.19 ± 0.89
a Statistically different from pre to post (p b 0.05).
b Out of standard at post measurement.
c Out of standard at pre measurement.
Table 5
PWCFT and sit-to-stand pre to post supplementation performance differences.
Treatment PWCFT pa STS pa
Pre (watts) Post (watts) % change Pre Post % change
ONS1200 (N = 13) 50.8 ± 22.6 58.8 ± 22.6 13.6 0.03 13.3 ± 3.6 17.1 ± 7.5 22.2 0.015
ONS800 (N = 15) 47.7 ± 17.4 57.3 ± 22.9 17.8 0.006 14.4 ± 2.5 14.9 ± 2.6 3.4
ONS (N = 16) 59.4 ± 27.7 55.9 ± 31.2 −6.3 16.6 ± 5.8 18.6 ± 6.6 10.7 0.002
Values reported as mean ± standard deviation (SD).
a p value represents pre to post difference.
937W.P. McCormack et al. / Experimental Gerontology 48 (2013) 933–939
the significant improvement reported by Stout et al. (2008) in a similar
cohort of older adults for the PWCFT test (28.6%). A recent study by del
Favero et al. (2012), measured physical capacity in two different ways,
one by time to exhaustion on a treadmill at 3.5 mphwith increasing el-
evation (TTE) and the other the limit of tolerance at a workload equiv-
alent to 75% of the difference between ventilatory anaerobic threshold
and VO2peak (TLIM) on a treadmill. Their results following 12-weeks
of β-alanine supplementation showed significant increases of 12.2% in
TTE and 36.5% in TLIM which is similar to the percent increase in phys-
ical working capacity reported by Stout et al. (2008) (28.6%). All three
studies examining β-alanine supplementation in older adults have
shown significant improvements in working capacity.
The difference in the results of the PWCFT seen in the present
study and the results by Stout et al. (2008) may be due to the differ-
ence in the total dose of β-alanine consumed during the supplement
period. The total dose of β-alanine consumed during the Stout et al.
(2008) study was approximately 216 g. This represents approximate-
ly 20% more β-alanine than that consumed by the ONS1200 (~181 g)
group and approximately 70%more β-alanine than the ONS800 group
(~125 g). This is supported by research from Hill et al. (2007) that
showed an improved performance in total cycling capacity with a
larger total dose of β-alanine supplementation.
Recently del Favero et al. (2012) reported supplementing a total
dose of 269 g of β-alanine which resulted in a mean increase of 85.4%
in muscle carnosine levels in a similar cohort of older men and
women. An increase in the muscle carnosine levels has been correlated
with increases in exercise capacity in both the young and old (Artioli et
al., 2010; del Favero et al., 2012; Hobson et al., 2012). One explanation
for the increase in exercise capacity with an increase in muscle
carnosine is the possible increase in muscle buffering capacity, which
will help maintain muscle pH levels in exercising muscle (Hobson et
al., 2012; Stout et al., 2008). This increase in buffering capacity within
the muscle may explain the significant increase in PWCFT observed in
groups ONS800 and ONS1200 in the present study. In support, del
Favero et al. (2012) demonstrated an increase in work capacity asmea-
sured on a treadmill, corresponded to a significant increase in muscle
carnosine levels.
As seen in previous β-alanine supplement research with older
adults (del Favero et al., 2012; Stout et al., 2008), the improvements
in working capacity were seen without a training intervention.
There are a number of implications in these findings. Research indi-
cates that as many as 75% of adults over the age of 60 years do not
meet physical activity recommendations as outlined by the United
States Department of Health and Human Services in 2008 (Tucker et
al., 2011). Without any intervention, this group of older adults will
continue to see a decline in working capacity, muscle mass, and mus-
cle function (Marcus et al., 2012). Supplementing with β-alanine and
thus maintaining high muscle carnosine content may lead to im-
provements in working capacity and perhaps encourage older adults
to maintain a more active lifestyle.
To our knowledge, there has been no research involving a training
intervention along with β-alanine supplementation in older adults. In
early work by de Vries et al. (1989), 10-weeks of aerobic training im-
proved PWCFT by 38.4 and 29.8% for older adults exercising at 85 and
70% of their pre-exercise PWCFT levels, respectively. Future research
needs to examine the impact of β-alanine supplementation and aero-
bic exercise training on working capacity in older adults.
In the present study, the GRIP (MAX and AVG) measures demon-
strated no improvement following 12 weeks supplementing β-alanine.
One explanation for this is the short duration of the activity, 3 to 5 s
for the GRIP. It has been suggested increasing muscle carnosine content
through β-alanine supplementation may not improve exercise per-
formance lasting less than 60 s (Hobson et al., 2012). In support, del
Favero et al. (2012) reported no significant improvement in the 30 s
STS test following 12-weeks of β-alanine supplementation. In contrast,
STS values in the current study were significantly improved in the
ONS1200 group. The difference between our results and del Favero et
al. (2012) is difficult to explain, but could be due to the reliability of
the STS or difference in level of fitness between participants in each
study. In the current study, baseline values for STS of the ONS1200
group averaged 13 compared to 16 in the β-alanine group in the del
Favero et al. (2012) study. Interestingly, the ONS1200 group and the
β-alanine group in the del Favero et al. (2012) study both averaged 17
STS post-testing. It is possible that if β-alanine supplementation in-
creases muscle carnosine levels, thus improving intra-muscular buffer-
ing capacity, this may delay fatigue and improve the STS performance.
Another explanation for the increase in STS performance could be the ef-
fect of carnosine on Ca2± ion sensitivity, leading to enhancements in
force production and reduced fatigue (Sale et al., 2010). Utilizing in
vitro techniques, Lamont andMiller (1992) demonstrated that the pres-
ence of carnosine reduced the amount of Ca2± required to produce
half-maximum tension in skeletal muscle. Similarly, Dutka and Lamb
(2004) showed, in vitro, increased Ca2± ion sensitivity of the contractile
apparatus, concluding that carnosine enhances force production as a
result of the sensitivity of the contractile apparatus to Ca2±, without
additional Ca2± release from the sarcoplasmic reticulum. While most
studies have determined no benefit of β-alanine supplementation for
exercise lasting less than 60 s in younger adults, our study suggests
that β-alanine may be beneficial for older men and women during a
maximal 30 second test. Future studies are needed to examine if
β-alanine supplementation is beneficial for intense anaerobic exercise
lasting less than 60 s.
A major limitation in this investigation was the fact that muscle
carnosine levels were not measured. Previous research (Baguet et al.,
2010; del Favero et al., 2012; Harris et al., 2006; Hill et al., 2007), how-
ever, using men and women (18–80 years) have shown that β-alanine
supplementation (3.2–6.4 g/day) for 28 to 84 days can significantly in-
creasemuscle carnosine content by asmuch as 85%. In addition, a recent
meta-analysis indicated that when ~179 g of β-alanine was consumed
over a period of 3–13 weeks there is an expected 2.85% improvement
in exercise performance (Hobson et al., 2012). In the current study, par-
ticipants consumed ~125 to 181 g over an 84 day periodwhich resulted
in a mean increase of 13.6% to 17.8% for the PWCFT. Therefore, while
muscle carnosine levels were not directly measured in the present
study, the results of previous investigations (Baguet et al., 2010; del
Favero et al., 2012; Harris et al., 2006; Hill et al., 2007) suggest that it
is likely that β-alanine supplementation resulted in an increase in mus-
cle carnosine concentrationwhichmay have an impact on exercise per-
formance. Future research is needed to examine the effect of low doses
of β-alanine supplementation as used in the current study, on changes
in muscle carnosine content and PWCFT. A second limitation in this
investigation was not performing a familiarization prior to testing. A fa-



























Fig. 1. Group differences in MQHANDGRIP when pre-supplement group differences were
accounted for. *ONS1200 had significantly greater increase than ONS and ONS800
(p b 0.05).
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research (de Vries et al., 1989; Stout et al., 2008) has shown the PWCFT
to be reliablewithout a familiarization trial. Finally, the rate of paresthe-
sia was relatively high with this low dose (2.4 g·day−1) of β-alanine.
This was possibly due to utilizing a non-sustained release formulation
of β-alanine.
5. Conclusions
The results of this study, showing a significant improvement in
working capacity following 12-weeks of β-alanine supplementation,
are in agreement with previous research (del Favero et al., 2012; Stout
et al., 2008). The unique finding in this study was two different total
doses of β-alanine (125 and 181 g) administered over 12-weeks led to
significant improvements in PWCFT in an older population. It is recom-
mended that future research investigate the combined effects of
β-alanine ingestion and exercise in an older adult population.
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